Holen Sie sich die Stockscreener-App
25.00
2.40%
-0.605
Akero Therapeutics Inc Aktie (AKRO) Neueste Nachrichten
Brokerages Set Akero Therapeutics, Inc. (NASDAQ:AKRO) PT at $46.83 - MarketBeat
H.C. Wainwright maintains buy on Akero stock - MSN
HC Wainwright Reiterates “Buy” Rating for Akero Therapeutics (NASDAQ:AKRO) - Defense World
Akero Therapeutics (NASDAQ:AKRO) Trading Up 8.4%Time to Buy? - MarketBeat
H.C. Wainwright maintains buy on Akero stock By Investing.com - Investing.com Canada
Akero Therapeutics (NASDAQ:AKRO) Given Buy Rating at HC Wainwright - MarketBeat
Akero Therapeutics (NASDAQ:AKRO) Stock Price Down 8.6%Should You Sell? - MarketBeat
(AKRO) Trading Report - Stock Traders Daily
Akero Therapeutics Completes Enrollment of the Double-Blind Portion of the Phase 3 Synchrony Real-World Study Evaluating Efruxifermin in Patients with Non-Invasively Diagnosed Mash or MASLD - Marketscreener.com
Akero Therapeutics Completes Phase 3 SYNCHRONY Enrollment for Groundbreaking MASH Treatment - StockTitan
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Shareholders to Reach Out - AccessWire
Akero Therapeutics, Inc. (NASDAQ:AKRO) Shares Sold by JPMorgan Chase & Co. - Defense World
JPMorgan Chase & Co. Sells 54,221 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Akero Therapeutics, Inc. (AKRO) and Encourages Shareholders to Learn More About the Investigation - AccessWire
Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Stockholders to Inquire about Securities Investigation - AccessWire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Akero Therapeutics, Inc. (AKRO) and Encourages Investors to Learn More About the Investigation - AccessWire
Non-Alcoholic Steatohepatitis Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Madrigal Pharmac, Inventiva Pharma, Zydus Therapeutics, Novo Nordisk A/S, Viking - The Globe and Mail
Akero Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Akero Therapeutics, Inc. (AKRO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - AccessWire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Akero Therapeutics, Inc. (AKRO) And Encourages Investors to Connect - AccessWire
Insider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Sells 10,000 Shares of Stock - MarketBeat
Akero Therapeutics COO Jonathan Young sells $280,330 in stock By Investing.com - Investing.com Nigeria
Akero Therapeutics COO Jonathan Young sells $280,330 in stock - Investing.com
AKRO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces an Investigation into Akero Therapeutics, Inc. and Encourages Investors to Contact the Firm - AccessWire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Stockholders to Reach Out - AccessWire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Akero Therapeutics, Inc. (AKRO) And Encourages Stockholders to Connect - AccessWire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Akero Therapeutics, Inc. (AKRO) and Encourages Stockholders to Learn More About the Investigation - AccessWire
Akero Therapeutics: Where This Potential MASH Play Stands Currently (NASDAQ:AKRO) - Seeking Alpha
2024-12-29 | Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Stockholders to Inquire about Securities Investigation | NDAQ:AKRO | Press Release - Stockhouse Publishing
Brokerages Set Akero Therapeutics, Inc. (NASDAQ:AKRO) Price Target at $46.83 - Defense World
Akero Therapeutics, Inc. (NASDAQ:AKRO) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Investors to Inquire about Securities Investigation - AccessWire
Geode Capital Management LLC Sells 48,027 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Geode Capital Management LLC Has $45.08 Million Stock Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO) - Defense World
Akero Therapeutics, Inc. (NASDAQ:AKRO) Shares Purchased by Barclays PLC - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Investors to Reach Out - AccessWire
Akero Therapeutics' senior VP Patrick Lamy sells $29,130 in stock By Investing.com - Investing.com Nigeria
Akero Therapeutics' senior VP Patrick Lamy sells $29,130 in stock - Investing.com India
Insider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) VP Sells 1,000 Shares of Stock - MarketBeat
Catriona Yale Sells 9,074 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock - MarketBeat
Akero Therapeutics chief scientific officer sells $118,172 in stock By Investing.com - Investing.com South Africa
Akero Therapeutics executive sells $264k in stock By Investing.com - Investing.com Canada
Akero Therapeutics chief scientific officer sells $118,172 in stock - Investing.com
Akero Therapeutics (NASDAQ:AKRO) Trading Down 4.1%What's Next? - MarketBeat
State Street Corp Has $71.81 Million Stock Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Fmr LLC Acquires 26,691 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - Defense World
Fmr LLC Purchases 26,691 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero Therapeutics (NASDAQ:AKRO) Shares Up 3.5%Here's What Happened - MarketBeat
Short Interest in Akero Therapeutics, Inc. (NASDAQ:AKRO) Drops By 9.1% - Defense World
AKERO THERAPEUTICS INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Akero Therapeutics, Inc.AKRO - The Eastern Progress Online
Akero Therapeutics, Inc. (NASDAQ:AKRO) Short Interest Down 9.1% in November - MarketBeat
Akero Therapeutics, Inc. (NASDAQ:AKRO) Shares Sold by BNP Paribas Financial Markets - Defense World
Akero Therapeutics' chief development officer sells $86,519 in stock By Investing.com - Investing.com South Africa
Akero Therapeutics chief scientific officer sells $148,933 in shares By Investing.com - Investing.com Canada
0.81%
7.69%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):